ModelMole

ModelMole is an autonomous molecular discovery platform developed by ModelMole that combines physics-based computational chemistry with machine learning to support drug discovery across oncology, antimicrobials, and regenerative medicine. Rather than relying solely on training data, the platform integrates high-accuracy physics-based methods with AI to explore regions of chemical space where datasets are sparse — an approach the company describes as "looking into the dark" — enabling identification of highly novel, effective, and patentable drug candidates that pure machine learning models may miss.

The platform is designed to be fully autonomous and infrastructure-agnostic, capable of running on enterprise clusters or a single workstation without dependency on specific vendors or infrastructure. It supports end-to-end drug discovery workflows and includes project support for users throughout the process.

Core Technology: Intelligent Multi-Model Orchestration

• Employs a proprietary Swarm AI system that utilises a network of multiple AI models rather than a single model, cross-referencing predictions to establish confidence levels across candidate assessments.
• Incorporates an automatic active learning loop that continuously improves system accuracy with each new problem solved, creating a compounding improvement cycle over time.
• Performs automatic gap-filling using computational chemistry to address areas where experimental data is limited.
• Physics-based methods are integrated alongside AI to extend reach beyond the boundaries of known chemical space.

End-to-End Discovery Workflow

• Supports the full drug discovery pipeline from initial drug design through to delivery, formulation, and stability and optimisation stages.
• Rapidly assesses biological systems and predicts promising candidates that may be missed by traditional approaches.
• Maintains active candidate pipelines spanning discovery, development, and approval phases.
• Used continuously by clients to develop and optimise both proprietary and collaborative drug candidates.

Platform Capabilities and Deployment

• Fully customisable to accommodate different research contexts and organisational requirements.
• Infrastructure-agnostic deployment supports a range of environments from large enterprise clusters to individual workstations.
• Dashboard interface provides visibility into pipeline statistics, molecule and protein counts, docking runs, weekly activity, top docking hits, recent runs, and pipeline status.
• Includes autonomous end-to-end process management with a unique follow-up mechanism designed to guide users toward optimal results.
• Full project support is available alongside the platform for teams requiring additional assistance.

The platform is positioned for use by biotech and pharmaceutical organisations seeking to identify novel candidates beyond what conventional AI-driven or traditional computational approaches can surface, with its active learning architecture designed to grow more capable with each successive project.